GSK to float HIV drug arm as part of recovery plan
            
        
            
        
        
        
            GlaxoSmithKline, battered by weak US drug sales and a bribery scandal in China, is looking to float its fast-growing HIV drugs business as part of a recovery plan that includes a fresh round of cost cutting.
        
        
        
        
            
                Business
                 • 22 Oct 14